Lineage Cell Therapeutics (BT3) Stock Overview
A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BT3 from our risk checks.
BT3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Lineage Cell Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.09 |
| 52 Week High | US$1.68 |
| 52 Week Low | US$0.91 |
| Beta | 1.51 |
| 1 Month Change | 1.67% |
| 3 Month Change | -10.47% |
| 1 Year Change | 20.88% |
| 3 Year Change | -12.48% |
| 5 Year Change | -51.59% |
| Change since IPO | -37.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| BT3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.9% | -1.2% | -2.5% |
| 1Y | 20.9% | 14.7% | -0.6% |
Return vs Industry: BT3 exceeded the German Biotechs industry which returned 13.8% over the past year.
Return vs Market: BT3 exceeded the German Market which returned -0.6% over the past year.
Price Volatility
| BT3 volatility | |
|---|---|
| BT3 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: BT3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BT3's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 75 | Brian Culley | www.lineagecell.com |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
Lineage Cell Therapeutics, Inc. Fundamentals Summary
| BT3 fundamental statistics | |
|---|---|
| Market cap | €279.57m |
| Earnings (TTM) | -€56.25m |
| Revenue (TTM) | €12.95m |
Is BT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BT3 income statement (TTM) | |
|---|---|
| Revenue | US$14.78m |
| Cost of Revenue | US$18.96m |
| Gross Profit | -US$4.18m |
| Other Expenses | US$60.03m |
| Earnings | -US$64.21m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -28.28% |
| Net Profit Margin | -434.44% |
| Debt/Equity Ratio | 0% |
How did BT3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/12 00:48 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lineage Cell Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |